Last mentioned: Feb 23, 2026
Expedited Pathway Formalized
FDA announces the formal implementation of quicker paths for gene therapy via surrogate endpoints.
START Pilot Launch
FDA initiates a pilot program for Support for clinical Trials Advancing Rare disease Therapeutics.
CBER Reorganization
The Office of Tissues and Advanced Therapies is elevated to a 'Super Office' to handle CGT volume.
Luxturna Approval
FDA approves the first gene therapy for an inherited disease, setting the initial regulatory precedent.
The U.S. Food and Drug Administration has established a streamlined regulatory pathway to expedite the development and review of gene therapies. This initiative focuses on leveraging surrogate endpoints and platform technologies to bring life-altering treatments for rare diseases to market faster.
This page surfaces every story mentioning U.S. Food and Drug Administration across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where U.S. Food and Drug Administration was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |